The CMS Medicare GLP-1 Bridge program began July 1, 2026, providing eligible Medicare Part D beneficiaries with access to certain GLP-1 medications for weight management at a $50 monthly copay. The program operates outside the traditional Medicare Part D benefit and uses a central processor to manage prior authorization, claims adjudication, and pharmacy payments. The program is currently scheduled to run through December 31, 2027, and is intended to expand access to GLP-1 therapies while CMS gathers data to inform future policy and coverage decisions.

When asked about the most significant patient barrier in the CMS Medicare GLP-1 Bridge program, respondents identified prior authorization requirements and the complexity of using a separate claims and benefit processor as the top concerns, each selected by 29% of respondents. Although the program offers a predictable $50 monthly copay, only 14% of respondents viewed the monthly out-of-pocket cost as the most significant barrier.

What is the most significant patient barrier in the CMS Medicare GLP-1 Bridge program?

Monthly out-of-pocket cost ($50): 14%

Prior authorization requirements: 29%

Complexity from a separate claims/benefit processor: 29%

Other access or awareness challenges: 14%

I am not familiar with the Bridge program: 14%